Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria

PURPOSE Chronic urticaria (CU) is a common and debilitating disease, and the need for effective treatment has increased. Omalizumab may be an alternative regimen in patients with CU who do not respond to conventional treatments. The aim of this study is to investigate the efficacy and to observe the clinical results of omlizumab in patients with refractory CU. METHODS We conducted a retrospec...

متن کامل

Increased Level of Basophil CD203c Expression Predicts Severe Chronic Urticaria

Increased FcεR1α expression with upregulated CD203c expression on peripheral basophils is seen in patients with chronic urticaria (CU). However, there has been no published report on the association between CD203c expression level and clinical disease activity in CU patients. To investigate whether the increase of basophil activation is associated with the disease activity of CU, we measured ba...

متن کامل

Chronic idiopathic urticaria: treatment with omalizumab.

Chronic idiopathic urticaria (CIU) is a common autoimmune skin condition characterized by spontaneously recurring hives for 6 weeks or longer. The new terminology used for CIU in most countries including Canada is chronic spontaneous urticaria (CSU). CSU is associated with significant psychosocial morbidity with a markedly negative impact on overall quality of life. Conventional approaches with...

متن کامل

adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness?

omalizumab is a recombinant humanized anti-ig e monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (csu). we report four patients with severe antihistamine-resistant csu, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: The Journal of Allergy and Clinical Immunology: In Practice

سال: 2016

ISSN: 2213-2198

DOI: 10.1016/j.jaip.2015.11.025